Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

M&A deals of Mosgorlombard will be financed by Promsvyazbank

2/19/24 MGKL

M.Video attracts strangers to its service areas

2/19/24 MVID

Kamaz cedes leadership to China's Sitrak

2/19/24 KMAZ

Polymetal agreed to sell Russian assets

2/19/24 POLY

Sovcombank will allocate 30% of 2023 profit for dividends

2/16/24 SVCB

Uralsib bailout completed ahead of schedule

2/16/24 USBN

Sovcombank intends to buy Home Bank

2/16/24 SVCB

Cherkizovo Group reported for 2023 by IFRS

2/16/24 GCHE

Reason for suspension of trades in IMCB shares was their growth

2/16/24 GEMA

OGK-2 reported for 2023 by RAS

2/16/24 OGKB